HK1207113A1 - Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai - Google Patents
Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnaiInfo
- Publication number
- HK1207113A1 HK1207113A1 HK15107660.7A HK15107660A HK1207113A1 HK 1207113 A1 HK1207113 A1 HK 1207113A1 HK 15107660 A HK15107660 A HK 15107660A HK 1207113 A1 HK1207113 A1 HK 1207113A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- rnai
- kras
- pharmaceutical composition
- composition capable
- suppressing expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671963P | 2012-07-16 | 2012-07-16 | |
PCT/JP2013/069322 WO2014013995A1 (ja) | 2012-07-16 | 2013-07-16 | KRAS遺伝子発現抑制RNAi医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207113A1 true HK1207113A1 (en) | 2016-01-22 |
Family
ID=49948821
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107660.7A HK1207113A1 (en) | 2012-07-16 | 2015-08-08 | Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai |
HK15108285.0A HK1207666A1 (en) | 2012-07-16 | 2015-08-26 | Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108285.0A HK1207666A1 (en) | 2012-07-16 | 2015-08-26 | Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai |
Country Status (10)
Country | Link |
---|---|
US (1) | US9913907B2 (ja) |
EP (1) | EP2873732A4 (ja) |
JP (1) | JP6272226B2 (ja) |
CN (1) | CN104471062A (ja) |
AU (1) | AU2013291125A1 (ja) |
CA (1) | CA2878314A1 (ja) |
HK (2) | HK1207113A1 (ja) |
SG (1) | SG11201502954TA (ja) |
TW (1) | TW201408324A (ja) |
WO (1) | WO2014013995A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2921573T3 (es) * | 2009-04-03 | 2022-08-29 | Dicerna Pharmaceuticals Inc | Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico |
TW201625310A (zh) * | 2014-06-04 | 2016-07-16 | Kyowa Hakko Kirin Co Ltd | CKAP5基因表現抑制RNAi醫藥組合物 |
CA2959358C (en) * | 2014-06-30 | 2022-07-26 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
US20190351039A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
EP3617314B1 (en) * | 2017-04-28 | 2023-02-15 | Kyowa Kirin Co., Ltd. | Oligonucleotide derivative or salt thereof |
CN112118847B (zh) * | 2018-03-02 | 2024-05-28 | 伊莱西奥治疗有限公司 | 包含突变kras序列和脂质的化合物及其用途 |
CN111534520A (zh) * | 2020-05-27 | 2020-08-14 | 深圳市疾病预防控制中心(深圳市卫生检验中心、深圳市预防医学研究所) | 特异抑制K-ras基因表达的慢病毒和重组载体构建及其应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1270198C (en) | 1984-08-08 | 1990-06-12 | Marcel B Bally | ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES |
ATE50983T1 (de) | 1985-01-07 | 1990-03-15 | Syntex Inc | Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
JP2923296B2 (ja) * | 1988-11-14 | 1999-07-26 | 株式会社ビタミン研究所 | 細胞への遺伝子導入法 |
JPH0696670B2 (ja) | 1988-11-16 | 1994-11-30 | 日本ポリウレタン工業株式会社 | 反応性安定化ポリオール組成物 |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
ES2186690T3 (es) | 1993-09-02 | 2003-05-16 | Ribozyme Pharm Inc | Acido nucleico enzimatico que contiene no-nucleotidos. |
US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
CA2237316C (en) | 1995-11-30 | 2012-06-26 | Vical Incorporated | Complex cationic lipids |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
WO1998058630A1 (en) | 1997-06-23 | 1998-12-30 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
AU1830200A (en) * | 1998-11-25 | 2000-06-13 | Vanderbilt University | Cationic liposomes for gene transfer |
IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
DE60141078D1 (de) | 2000-10-04 | 2010-03-04 | Kyowa Hakko Kirin Co Ltd | Methode zur beschichtung feiner teilchen mit einem lipidfilm |
US20020132788A1 (en) | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
PT2280070E (pt) | 2001-07-23 | 2015-10-29 | Univ Leland Stanford Junior | Métodos e composições para inibição mediada por iarn da expressão génica em mamíferos |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
KR20070104575A (ko) | 2005-01-28 | 2007-10-26 | 교와 핫꼬 고교 가부시끼가이샤 | 표적 유전자의 발현을 억제하는 조성물 |
GB0505969D0 (en) | 2005-03-23 | 2005-04-27 | Novartis Ag | Organic compounds |
CA2679388A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
CA3044134A1 (en) | 2008-01-02 | 2009-07-09 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
CN102325534B (zh) * | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
ES2921573T3 (es) * | 2009-04-03 | 2022-08-29 | Dicerna Pharmaceuticals Inc | Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico |
JP5902616B2 (ja) * | 2010-04-28 | 2016-04-13 | 協和発酵キリン株式会社 | カチオン性脂質 |
US20140045913A1 (en) * | 2011-12-12 | 2014-02-13 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising combination of cationic lipid |
EP2792367A4 (en) | 2011-12-12 | 2015-09-30 | Kyowa Hakko Kirin Co Ltd | LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS |
-
2013
- 2013-07-16 JP JP2014525829A patent/JP6272226B2/ja not_active Expired - Fee Related
- 2013-07-16 CN CN201380037777.9A patent/CN104471062A/zh active Pending
- 2013-07-16 US US13/943,038 patent/US9913907B2/en not_active Expired - Fee Related
- 2013-07-16 TW TW102125430A patent/TW201408324A/zh unknown
- 2013-07-16 WO PCT/JP2013/069322 patent/WO2014013995A1/ja active Application Filing
- 2013-07-16 AU AU2013291125A patent/AU2013291125A1/en not_active Abandoned
- 2013-07-16 SG SG11201502954TA patent/SG11201502954TA/en unknown
- 2013-07-16 CA CA2878314A patent/CA2878314A1/en not_active Abandoned
- 2013-07-16 EP EP13820367.4A patent/EP2873732A4/en not_active Withdrawn
-
2015
- 2015-08-08 HK HK15107660.7A patent/HK1207113A1/xx unknown
- 2015-08-26 HK HK15108285.0A patent/HK1207666A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TW201408324A (zh) | 2014-03-01 |
WO2014013995A1 (ja) | 2014-01-23 |
EP2873732A1 (en) | 2015-05-20 |
EP2873732A4 (en) | 2016-03-23 |
CN104471062A (zh) | 2015-03-25 |
JP6272226B2 (ja) | 2018-01-31 |
CA2878314A1 (en) | 2014-01-23 |
US9913907B2 (en) | 2018-03-13 |
SG11201502954TA (en) | 2015-05-28 |
AU2013291125A1 (en) | 2015-01-22 |
US20140044755A1 (en) | 2014-02-13 |
HK1207666A1 (en) | 2016-02-05 |
JPWO2014013995A1 (ja) | 2016-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281295A (en) | Preparations and methods for inhibiting expression of the ALAS1 gene | |
HK1204770A1 (en) | Compartmentalized method of nucleic acid delivery and compositions and uses thereof | |
HK1211316A1 (en) | Mirna modulators of thermogenesis mirna | |
EP2677865A4 (en) | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION | |
EP2691121A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | |
HK1207666A1 (en) | Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai | |
EP2855680A4 (en) | COMPOSITIONS AND METHODS FOR SILENCING GENE EXPRESSION | |
HK1209621A1 (en) | Inhibitors of the mir-15 family of micro-rnas mir-15 rna | |
EP2917314A4 (en) | OLIGOMERATZUSAMMENSETZUNG | |
SI2691083T1 (sl) | Farmacevtski sestavek sitagliptina | |
HRP20180567T1 (hr) | Farmaceutski pripravak omeprazola | |
ZA201504442B (en) | Regulation of gene expression | |
HK1214160A1 (zh) | 抑制劑的藥物組合物 | |
PT3524260T (pt) | Composições farmacêuticas para o tratamento de inapetência | |
HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
ZA201402165B (en) | Compositions of lopinavir | |
GB201100786D0 (en) | Pharmaceutical compositions of immunosuppressants | |
EP2884964A4 (en) | PHARMACEUTICAL COMPOSITION OF PROPOFOL | |
EP2739738A4 (en) | USE OF INTEGRASE FOR TARGETED GENE EXPRESSION | |
IL233445A0 (en) | Methods and preparations for gene transfer | |
IL233879A0 (en) | Dry powdered dnase i preparations | |
GB201104632D0 (en) | Use of medicament |